SCHEMBL27349791

SCHEMBL27349791

COC(=O)[C@H](Cn1nnc2ccccc21)NC(=O)OC(C)(C)C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 2/20 0.50
▸ APAF1 O14727 1/20 0.50
▸ MAPT P10636 4/20 0.47
▸ LMNA P02545 2/20 0.47
▸ EGLN3 Q9H6Z9 1/20 0.44
▸ KDM4E B2RXH2 1/20 0.44
▸ USP2 O75604 1/20 0.43
▸ MDM2 Q00987 1/20 0.43
▸ GAA P10253 2/20 0.43
▸ MGAM O43451 1/20 0.43
▸ AMY1A P0DUB6 1/20 0.43
▸ SI P14410 1/20 0.43
▸ MGAM2 Q2M2H8 1/20 0.43
▸ RAB9A P51151 4/20 0.43
▸ SMN1; SMN2 Q16637 4/20 0.43
▸ NPC1 O15118 2/20 0.43
▸ HTT P42858 1/20 0.43
▸ KLK5 Q9Y337 1/20 0.42
▸ ALDH1A1 P00352 3/20 0.42
▸ KMT2A Q03164 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27349789 0.90 APAF1 (0.57) POLBAPAF1MAPTLMNAEGLN3
SCHEMBL27349797 0.89 APAF1 (0.50) POLBAPAF1MAPTLMNAEGLN3
SCHEMBL496471 0.78 KLK5 (0.52) POLBAPAF1MAPTLMNAUSP2
SCHEMBL496472 0.78 KLK5 (0.52) POLBAPAF1MAPTLMNAUSP2
SCHEMBL27349682 0.78 CTSK (0.39) MAPTSMN1; SMN2HTTKLK5ALDH1A1
SCHEMBL18803150 0.77 BCHE (0.49) POLBAPAF1MAPTEGLN3KDM4E
SCHEMBL29964193 0.77 BCHE (0.49) POLBAPAF1MAPTEGLN3KDM4E
SCHEMBL5603250 0.76 HDAC3 (0.42) KDM4ERAB9ASMN1; SMN2NPC1KLK5
SCHEMBL30714784 0.76 MAPT (0.53) POLBMAPTRAB9ASMN1; SMN2NPC1
SCHEMBL29964106 0.75 BCHE (0.47) POLBAPAF1MAPTEGLN3KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250376464-A1 Compounds for treatment a coronavirus infection TRAWSFYNYDD THERAPEUTICS INC (US) 2025-12-11 — — US disclosed
EP-4540227-A2 COMPOUNDS FOR TREATMENT A CORONAVIRUS INFECTION Trawsfynydd Therapeutics, Inc. (US) 2025-04-23 — — EP disclosed
WO-2023245162-A2 COMPOUNDS FOR TREATMENT A CORONAVIRUS INFECTION TRAWSFYNYDD THERAPEUTICS, INC. (US) 2023-12-21 — — WO disclosed
WO-2023245162-A2 COMPOUNDS FOR TREATMENT A CORONAVIRUS INFECTION TRAWSFYNYDD THERAPEUTICS, INC. (US) 2023-12-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250376464-A1 Compounds for treatment a coronavirus infection ACE2, ACE, TMPRSS2 POLB 1219/4885APAF1 78/4885MAPT 4009/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback